Grant: Operating Grant
University of Ottawa
$100,000.00
Design, Synthesis and Evaluation of Transglutaminase Inhibitors as Potential Cancer Therapeutics
FY 2015-16
Summary
Transglutaminases are multifunctional enzymes that catalyse the cross-linking of proteins outside the cell, and participate in signalling inside the cell. However, a growing body of recent evidence has linked the unregulated activity of these enzymes to the spreading of cancer cells. In light of this correlation, we will develop inhibitors for transglutaminases that will halt the proliferation of cancer cells and render them more susceptible to chemotherapy. The results of this study will impact our understanding of the role of transglutaminases in cancer and lead to the development of new therapeutic methods.
Department
Program
Operating Grant
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
333028
Name
Keillor Jeffrey W
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Design, Synthesis and Evaluation of Transglutaminase Inhibitors as Potential Cancer Therapeutics
Programtype2
Operating Grants
Orgnameinp2
University of Ottawa
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant
Keyworddelim
Cancer; Cancer Stem Cells; Chemoresistance; Drug Design; Enzyme Inhibition; Medicinal Chemistry; Metastasis; Pharmacodynamics; Pharmacokinetics; Transglutaminase
Abstract
Transglutaminases are multifunctional enzymes that catalyse the cross-linking of proteins outside the cell, and participate in signalling inside the cell. However, a growing body of recent evidence has linked the unregulated activity of these enzymes to the spreading of cancer cells. In light of this correlation, we will develop inhibitors for transglutaminases that will halt the proliferation of cancer cells and render them more susceptible to chemotherapy. The results of this study will impact our understanding of the role of transglutaminases in cancer and lead to the development of new therapeutic methods.
Competitiondate
201505
Approvedterm2
1 yr 0 mth
Pinamesdelim
Keillor, Jeffrey W
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~